EMRO., Incorporated (058970) Fair Value & Analysis
Technology · KR · Market cap 265B KRW
Fair value as of: Jun 24, 2026
Analysis
EMRO., Incorporated (058970) currently trades at 16,570 KRW, while our model-based Fair Value estimate is 4,033 KRW — implying the stock looks roughly 75.7% overvalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
EMRO., Incorporated. provides supply chain management software in South Korea and internationally. Its procurement and purchase solutions include design to source solutions, such as BOM design and cost collaboration, and cost estimation; source to contract solutions, including price structure analysis, scenario-based sourcing analysis, quotation analyzer, and bid analysis and comparison; procure to pay solutions, such as item similarity analysis, and support solutions for E2E and PO processes; supplier management, such as supplier 360 degree view and onboarding, performance evaluation, and risk management; data analysis solutions, such as data integration, and dashboard creation and publishing; and agentic AI software solutions, such as Ask Caidentia, evaluation opinion drafter, and RFX draft generator. The company was founded in 2000 and is based in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is EMRO., Incorporated (058970) undervalued?
What is the fair value of 058970?
What is the quality score of 058970?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.